Ignite Creation Date:
2024-05-06 @ 8:28 PM
Last Modification Date:
2024-10-26 @ 3:28 PM
Study NCT ID:
NCT06395870
Status:
RECRUITING
Last Update Posted:
2024-05-31
First Post:
2024-04-29
Brief Title:
Targeting CD19CD20 Dual-targeted Cell in Patients With RelapsedRefractory B-cell Non-Hodgkin Lymphoma
Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Organization:
Tianjin Medical University Cancer Institute and Hospital
Study Overview
Official Title:
A Phase I Open-label Clinical Study to Evaluate the Safety Tolerability and Efficacy of LUCAR-G39D a Dual-targeted Cell Preparation Targeting CD19CD20 in Patients With RelapsedRefractory B-cell Non-Hodgkin Lymphoma
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A phase I open-label clinical study to evaluate the safety tolerability and efficacy of LUCAR-G39D a dual-targeted cell preparation targeting CD19CD20 in patients with relapsedrefractory B-cell non-Hodgkin lymphoma
Detailed Description:
This is an open-label dose-escalationdose extension study to assess the safety tolerability and efficacy of LUCAR-G39D in the patient 18 years of age with relapsed or refractory B-cell non-Hodgkin lymphoma Subjects who meet the eligibility criteria will receive a single dose of LUCAR-G39D injection The study will include the following sequential phases screening pre-treatment lymphodepleting chemotherapy treatment and follow-up
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None